{"id":"NCT01150097","sponsor":"Novartis Pharmaceuticals","briefTitle":"Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients","officialTitle":"Extension Study to the Multicenter, Open-label, Randomized, Controlled Study CRAD001H2304 to Evaluate the Long-term Efficacy and Safety of Concentration-controlled Everolimus in Liver Transplant Recipient","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03-31","primaryCompletion":"2013-05-03","completion":"2013-05-03","firstPosted":"2010-06-24","resultsPosted":"2014-05-30","lastUpdate":"2018-11-07"},"enrollment":284,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Liver Transplant Recipient"],"interventions":[{"type":"DRUG","name":"Tacrolimus (reduced tacrolimus)","otherNames":["FK-506,","fujimycin,","Prograf,","Advagraf,","Protopic"]},{"type":"DRUG","name":"Everolimus (reduced tacrolimus)","otherNames":["RAD001,","Zortress,","Certican,","Afinitor"]},{"type":"DRUG","name":"Tacrolimus (tacrolimus elimination)","otherNames":["FK-506,","fujimycin,","Prograf,","Advagraf,","Protopic"]},{"type":"DRUG","name":"Everolimus (tacrolimus elimination)","otherNames":["RAD001,","Zortress,","Certican,","Afinitor"]},{"type":"DRUG","name":"Tacrolimus (tacrolimus control)","otherNames":["FK-506,","fujimycin,","Prograf,","Advagraf,","Protopic"]},{"type":"DRUG","name":"Corticosteroids","otherNames":[]}],"arms":[{"label":"Everolimus + reduced tacrolimus","type":"EXPERIMENTAL"},{"label":"Tacrolimus elimination","type":"EXPERIMENTAL"},{"label":"Tacrolimus control","type":"ACTIVE_COMPARATOR"}],"summary":"The reason for this extension is to evaluate the long-term safety and efficacy of two concentration-controlled everolimus regimen in de novo liver transplant recipients. The most important long-term safety assessments include evaluation of renal function, progression of HCV related allograft fibrosis, and other treatment related effects at Month 36 post-transplantation compared to extension baseline (Months 24 post-transplantation).","primaryOutcome":{"measure":"Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death","timeFrame":"from months 24 to 36","effectByArm":[{"arm":"Everolimus + Reduced Tacrolimus","deltaMin":2,"sd":null},{"arm":"Tacrolimus Elimination","deltaMin":1,"sd":null},{"arm":"Tacrolimus Control","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":57,"countries":["United States","Argentina","Australia","Belgium","Brazil","Colombia","Czechia","France","Germany","Ireland","Italy","Netherlands","Russia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":106},"commonTop":["Diarrhoea","Hypertension","Nasopharyngitis","Hypercholesterolaemia","Fatigue"]}}